No Data
Beijing Tiantan Biological Products Corporation (600161.SH): The holding subsidiary has obtained the GMP certificate from Turkey.
On January 22, Gelonghui reported that Beijing Tiantan Biological Products Corporation (600161.SH) announced that its holding subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. recently received a GMP certificate issued by the Turkish Ministry of Health's Medicines and Medical Instruments Authority. The GMP certification pertains to the intravenous human immunoglobulin production line located in the Chengdu Rongsheng blood products manufacturing workshop, which has a designed processing capacity of 1,200 tons per year.
Tiantan Biotech: Tiantan Biotech 2024 Annual Performance Report Announcement
Tiantan Biotech 2024 Annual Results Report Announcement
Beijing Tiantan Biological Products Corporation (600161.SH): Net income for the fiscal year 2024 is 1.547 billion yuan, an increase of 39.42% year-on-year.
On January 20, Gelonghui reported that Beijing Tiantan Biological Products Corporation (600161.SH) announced its preliminary performance for 2024. In 2024, mainly due to the increase in product sales and price increases, sales revenue grew, with total operating revenue of 6.034 billion yuan; an increase of 16.47% compared to the same period last year, and a net income attributable to shareholders of 1.547 billion yuan; up 39.42% year-on-year. In 2024, the company implemented various measures to enhance plasma collection, achieving plasma collection of 27 at 85 single plasma collection companies (including the single plasma collection company under Wuhan Zhongyuan Ruide Biological Products Co., Ltd.).
Beijing Tiantan Biological Products Corporation (600161.SH): The clinical trial summary report of recombinant human coagulation Indicators VIIa for injection has shown good efficacy.
Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary Chengdu Rongsing Pharmaceutical Co., Ltd. (abbreviated as "Cheng...")
Beijing Tiantan Biological Products Corporation (600161.SH): signed a leasing contract with a related party.
On December 30, Ge Longhui reported that Beijing Tiantan Biological Products Corporation (600161.SH) announced that the company owns the land use rights and the ownership of its above-ground attachments at No. 2, B District, Shuangqiao Road, Chaoyang District, Peking. The company has signed a lease agreement with the related party Beijing China National Pharmaceutical Asset Management Co., Ltd. (hereinafter referred to as "National Pharmaceutical Asset Company"), leasing part of the assets of the park (actual building area of 18,676.80 square meters) to National Pharmaceutical Asset Company. The aforementioned lease agreement will expire on December 31, 2024.